Project Grant R21CA299166
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$225K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $128,100.00 to the New York Blood Center, Inc. to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The goal is to address barriers to equitable access to SCD gene therapy, which often requires extensive leukapheresis and myeloablative conditioning. The...
This Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), provides $101,491 to Cold Spring Harbor Laboratory (CSHL) to conduct research on understanding and targeting senescence in clonal hematopoiesis (CH). The two-part research project aims to: 1) identify inflammatory mediators of CH-mutant hematopoietic stem and progenitor cells (HSPCs) and evaluate their potential as therapeutic targets; and 2) investigate the role...
This Project Grant award of $433,895.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will investigate the psychosocial, ethical, and clinical implications of incidental findings of clonal hematopoiesis (CH) in healthy hematopoietic stem cell (HSC) donors.
The key products/services to be delivered include:
Qualitative examination of the psychosocial impact of receiving information about incidental CH findings through focus...
This federal Project Grant award of $169,156 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research conducted by The Washington University to optimize hematopoietic stem cell transplantation (HSCT) for treating non-malignant diseases, with a focus on sickle cell disease (SCD).
The key objectives of this 5-year award are to: 1) Evaluate novel stem cell mobilization regimens to generate a sufficient...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $336,000 to the Van Andel Research Institute (VAI) to characterize the role of germline genetic variation and viral exposures as determinants of susceptibility to hematological diseases, particularly pediatric acute myeloid leukemia (AML). The research aims to identify genetic and viral factors that may interact with structural chromosomal variants to increase the risk of AML and...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $445,996 to the University of Pittsburgh to conduct research examining how mitigating oxidative stress at telomeres can improve the function of T cells in adoptive cell therapies against cancer.
Specifically, the research aims to determine the role of oxidative damage at telomeres on T cell function, and how protecting telomeres with an antioxidant...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
The National Cancer Institute (NCI) awarded a $458,698 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Regents of the University of Michigan. The grant, titled "Genes Regulating Stem and Progenitor Cell Expansion and Relapse in Acute Myeloid Leukemia", aims to study novel genes that influence normal and leukemic stem/progenitor cell expansion, and their contributions to therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year project...
This $430,956 Project Grant award from the National Institute on Aging (NIA), part of the Aging Research federal grant program (CFDA 93.866), supports research to identify novel clinical and 'omic risk factors, such as telomere length, mitochondrial copy number, and clonal hematopoiesis, for organ dysfunction and early mortality in sickle cell disease (SCD). The funding will also be used to discover proteomic and glycoproteomic biomarkers associated with premature mortality in SCD. The goal...